REGENXBIO (RGNX)
(Real Time Quote from BATS)
$15.86 USD
-0.18 (-1.12%)
Updated Apr 25, 2024 12:59 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
RGNX 15.86 -0.18(-1.12%)
Will RGNX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RGNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RGNX
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
RGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
Other News for RGNX
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Edgewise gets EU orphan drug status for muscular dystrophy drug
Where Regenxbio Stands With Analysts
Commit To Purchase REGENXBIO At $7.50, Earn 10.1% Annualized Using Options
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD